MXCT Quote, Financials, Valuation and Earnings

IRIDEX has a net margin of -98.76% compared to MaxCyte's net margin of -14.17%. MaxCyte's return on equity of -19.59% beat IRIDEX's return on equity of -218.69%.

MaxCyte has a consensus price target of $7.00, signalling upside risk potential of 218.18%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 127.27%. Given that MaxCyte has higher upside potential than IRIDEX, analysts believe MaxCyte is more attractive than IRIDEX.

MaxCyte has a beta of 0.282, which suggesting that the stock is 71.762% less volatile than S&P 500. In comparison IRIDEX has a beta of 0.615, suggesting its less volatile than the S&P 500 by 38.546%.

MaxCyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MaxCyte pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.

MaxCyte quarterly revenues are $10.4M, which are smaller than IRIDEX quarterly revenues of $11.9M. MaxCyte's net income of -$10.3M is lower than IRIDEX's net income of -$1.7M. Notably, MaxCyte's price-to-earnings ratio is -- while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MaxCyte is 6.15x versus 0.30x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -98.76% compared to MaxCyte's net margin of -35.24%. MaxCyte's return on equity of -19.59% beat Myomo's return on equity of -38.11%.

MaxCyte has a consensus price target of $7.00, signalling upside risk potential of 218.18%. On the other hand Myomo has an analysts' consensus of $8.70 which suggests that it could grow by 284.96%. Given that Myomo has higher upside potential than MaxCyte, analysts believe Myomo is more attractive than MaxCyte.

MaxCyte has a beta of 0.282, which suggesting that the stock is 71.762% less volatile than S&P 500. In comparison Myomo has a beta of 1.489, suggesting its more volatile than the S&P 500 by 48.933%.

MaxCyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MaxCyte pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

MaxCyte quarterly revenues are $10.4M, which are larger than Myomo quarterly revenues of $9.8M. MaxCyte's net income of -$10.3M is lower than Myomo's net income of -$3.5M. Notably, MaxCyte's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MaxCyte is 6.15x versus 2.28x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

NanoVibronix has a net margin of -98.76% compared to MaxCyte's net margin of -243.42%. MaxCyte's return on equity of -19.59% beat NanoVibronix's return on equity of -63.03%.

MaxCyte has a consensus price target of $7.00, signalling upside risk potential of 218.18%. On the other hand NanoVibronix has an analysts' consensus of -- which suggests that it could grow by 81333.23%. Given that NanoVibronix has higher upside potential than MaxCyte, analysts believe NanoVibronix is more attractive than MaxCyte.

MaxCyte has a beta of 0.282, which suggesting that the stock is 71.762% less volatile than S&P 500. In comparison NanoVibronix has a beta of 1.754, suggesting its more volatile than the S&P 500 by 75.399%.

MaxCyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoVibronix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MaxCyte pays -- of its earnings as a dividend. NanoVibronix pays out -- of its earnings as a dividend.

MaxCyte quarterly revenues are $10.4M, which are larger than NanoVibronix quarterly revenues of $1M. MaxCyte's net income of -$10.3M is lower than NanoVibronix's net income of -$2.5M. Notably, MaxCyte's price-to-earnings ratio is -- while NanoVibronix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MaxCyte is 6.15x versus 0.16x for NanoVibronix. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of -98.76% compared to MaxCyte's net margin of -77.93%. MaxCyte's return on equity of -19.59% beat Stereotaxis's return on equity of -174.6%.

MaxCyte has a consensus price target of $7.00, signalling upside risk potential of 218.18%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 96.51%. Given that MaxCyte has higher upside potential than Stereotaxis, analysts believe MaxCyte is more attractive than Stereotaxis.

MaxCyte has a beta of 0.282, which suggesting that the stock is 71.762% less volatile than S&P 500. In comparison Stereotaxis has a beta of 1.460, suggesting its more volatile than the S&P 500 by 46.028%.

MaxCyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MaxCyte pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

MaxCyte quarterly revenues are $10.4M, which are larger than Stereotaxis quarterly revenues of $7.5M. MaxCyte's net income of -$10.3M is lower than Stereotaxis's net income of -$5.8M. Notably, MaxCyte's price-to-earnings ratio is -- while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MaxCyte is 6.15x versus 7.18x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.